Effector Cell Institute is developing Nagrestipen (ECI 301) for the treatment of cancer. Preclinical studies of ECI 301, a mutant derivative of macrophage inhibitory protein-1α (a single amino-acid substituted MIP-1α), have shown that its administration can improve the antitumor effects of radiotherapy in a manner associated with a tumor-independent abscopal effect. ECI 301 enhanced tumor growth inhibition and the abscopal effect (an effect distal to the target) following local antitumor therapy such as radiation, radiofrequency ablation (RFA), or hyperthermia treatment. Nagrestipen has been used in trials studying the treatment of cancer.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Macrophage inflammatory protein derivative ECI301 enhances the alarmin-associated abscopal benefits of tumor radiotherapy. | 2014-09-15 |
|
| Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. | 2008-02-15 |
|
| USAN Council. List No. 404. New names. Nagrestipen. | 1998-05 |
Sample Use Guides
Colon26 adenocarcinoma-bearing BALB/c mice, repeated daily administration (over 3-5 consecutive days) of 2 mug per mouse ECI 301 after local irradiation of 6 Gy prolonged survival without significant toxicity, and in about half of the treated mice, the tumor was completely eradicated.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C129820
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB12075
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
PRIMARY | |||
|
7429
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
PRIMARY | |||
|
II-24
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
PRIMARY | |||
|
CHEMBL2108471
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
PRIMARY | |||
|
SUB09136MIG
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
PRIMARY | |||
|
100000084440
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
PRIMARY | |||
|
9350121Z8S
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
PRIMARY | |||
|
166089-33-4
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
PRIMARY | |||
|
C98294
Created by
admin on Mon Mar 31 21:33:01 GMT 2025 , Edited by admin on Mon Mar 31 21:33:01 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
